BIOMAT Database Logo BIOMAT Database Logo

Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. 2010

Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. h.sutherland@auckland.ac.nz

Recently described biphenyl analogues of the antituberculosis drug PA-824 displayed improved potencies against M. tuberculosis but were poorly soluble. Heterobiaryl analogues of these, in which the first phenyl ring was replaced with various 5-membered ring heterocycles, were prepared with the aim of identifying potent new candidates with improved aqueous solubility. The compounds were constructed by coupling the chiral 2-nitroimidazooxazine alcohol with various halomethyl-substituted arylheterocycles, by cycloadditions to a propargyl ether derivative of this alcohol, or by Suzuki couplings on haloheterocyclic methyl ether derivatives. The arylheterocyclic compounds were all more hydrophilic than their corresponding biphenyl analogues, and several showed solubility improvements. 1-Methylpyrazole, 1,3-linked-pyrazole, 2,4-linked-triazole, and tetrazole analogues had 3- to 7-fold higher MIC potencies against replicating M. tb than predicted by their lipophilicities. Two pyrazole analogues were >10-fold more efficacious than the parent drug in a mouse model of acute M. tb infection, and one displayed a 2-fold higher solubility.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
January 2009, Chemistry (Weinheim an der Bergstrasse, Germany),
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Synthesis and structure-activity relationships of 1beta-methylcarbapenems with quaternary ammonium side chains.
August 1998, The Journal of antibiotics,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.
March 2009, Journal of medicinal chemistry,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.
November 2002, Bioorganic & medicinal chemistry letters,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Synthesis and anti-inflammatory activity of new N-acyl-2-pyrazolines bearing homologous alkyloxy side chains.
January 2014, Acta chimica Slovenica,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.
July 2012, European journal of medicinal chemistry,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
July 2007, Bioorganic & medicinal chemistry letters,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.
September 2011, ChemMedChem,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Synthesis and structure-activity relationships of heterocyclic compounds containing a trimethoxyarene function.
February 1976, Journal of medicinal chemistry,
Hamish S Sutherland, and Adrian Blaser, and Iveta Kmentova, and Scott G Franzblau, and Baojie Wan, and Yuehong Wang, and Zhenkun Ma, and Brian D Palmer, and William A Denny, and Andrew M Thompson
Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives.
November 1994, Journal of medicinal chemistry,
Copied contents to your clipboard!